CYP2D6 and breast cancer: Nineteen of the included studies reported that CYP2D6 genotypes were not associated with survival in breast cancer patients treated with tamoxifen (Refs 16, 24, 29, 30, 43, 44, 47–50, 51, 53, 55, 59, 62, 64, 67, 68, 73).